{"nctId":"NCT01959880","briefTitle":"CPG Styles Study: A Study of the Safety of the Contour Profile Gel Breast Implants (CPG Styles Study)","startDateStruct":{"date":"2013-08"},"conditions":["Breast Augmentation","Breast Reconstruction","Breast Revision"],"count":1891,"armGroups":[{"label":"Primary Augmentation","type":"OTHER","interventionNames":["Device: The Contour Profile Gel (CPG) breast implants"]},{"label":"Primary Reconstruction","type":"OTHER","interventionNames":["Device: The Contour Profile Gel (CPG) breast implants"]},{"label":"Revison Augmentation","type":"OTHER","interventionNames":["Device: The Contour Profile Gel (CPG) breast implants"]},{"label":"Revision Reconstruction","type":"OTHER","interventionNames":["Device: The Contour Profile Gel (CPG) breast implants"]}],"interventions":[{"name":"The Contour Profile Gel (CPG) breast implants","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject is genetic female, 18 years of age or older\n* A candidate for: Primary breast augmentation (general breast enlargement), Primary breast reconstruction (for trauma, loss of breast tissue due to mastectomy, malignancy, contralateral post-reconstruction symmetry, congenital deformity, including asymmetry), or Revision surgery (previous augmentation or reconstruction with silicone-filled or saline-filled implants)\n* Signs the Informed Consent\n* Agrees to return device to Mentor if explant necessary\n* Agrees to comply with follow-up procedures, including returning for all follow-up visits\n\nExclusion Criteria:\n\n* Subject is pregnant\n* Has nursed a child within three months of study enrollment\n* Been implanted with any silicone implant other than breast implants (e.g. silicone artificial joints or facial implants)\n* Confirmed diagnosis of the following rheumatic diseases or syndromes: SLE, Sjogren's syndrome, scleroderma, polymyositis, or any connective tissue disorder, rheumatoid arthritis, crystalline arthritis, infectious arthritis, spondylarthropathies, any other inflammatory arthritis, fibromyalgia, or chronic fatigue syndrome\n* Currently has a condition that could compromise or complicate wound healing (except reconstruction subjects)\n* Subject in Augmentation cohort and has diagnosis of active cancer of any type. (Exception is low-grade non-metastasizing skin cancer)\n* Infection or abscess anywhere in the body\n* Demonstrates tissue characteristics which are clinically incompatible with implant (e.g. tissue damage resulting from radiation, inadequate tissue, or compromised vascularity)\n* Possesses any condition, or is under treatment for any condition which, in the opinion of the investigator and/or consulting physicians(s), may constitute an unwarranted surgical risk\n* Anatomic or physiologic abnormality which could lead to significant postoperative adverse events\n* Demonstrates characteristics that are unrealistic/unreasonable with the risks involved with the surgical procedure\n* Premalignant breast disease without a subcutaneous mastectomy\n* Untreated or inappropriately treated breast malignancy, without mastectomy\n* Are HIV positive\n* Work for Mentor or the study doctor or are directly-related to anyone that works for Mentor or the study doctor","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"6-Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Any Reoperation","description":"Time of occurrence calculated as the number of days from the date of the implant procedure to the onset date of the event. Patients were censored as of the date of their last office visit, the 120 month time point, or the date of explantation of all initial study devices, whichever was earliest.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null},{"groupId":"OG001","value":"31.7","spread":null},{"groupId":"OG002","value":"13.8","spread":null},{"groupId":"OG003","value":"31.3","spread":null}]}]}]},{"type":"PRIMARY","title":"6-Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Baker III, IV Capsular Contracture","description":"Baker III was identified as \"firm with visible distortion\" and Baker IV was identified as \"obvious spherical distortion\". Time of occurrence calculated as the number of days from the date of the implant procedure to the onset date of the event. Patients were censored as of the date of their last office visit, the 120 month time point, or the date of explantation of all initial study devices, whichever was earliest.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null},{"groupId":"OG001","value":"8.8","spread":null},{"groupId":"OG002","value":"1.6","spread":null},{"groupId":"OG003","value":"7.8","spread":null}]}]}]},{"type":"PRIMARY","title":"6-Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Infection","description":"Time of occurrence calculated as the number of days from the date of the implant procedure to the onset date of the event. Patients were censored as of the date of their last office visit, the 120 month time point, or the date of explantation of all initial study devices, whichever was earliest.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"2.4","spread":null},{"groupId":"OG002","value":"1.0","spread":null},{"groupId":"OG003","value":"2.3","spread":null}]}]}]},{"type":"PRIMARY","title":"6-Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Explantation With or Without Replacement","description":"Time of occurrence calculated as the number of days from the date of the implant procedure to the onset date of the event. Patients were censored as of the date of their last office visit, the 120 month time point, or the date of explantation of all initial study devices, whichever was earliest.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null},{"groupId":"OG001","value":"20.2","spread":null},{"groupId":"OG002","value":"8.6","spread":null},{"groupId":"OG003","value":"16.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":1132},"commonTop":[]}}}